收费全文 | 3125880篇 |
免费 | 248484篇 |
国内免费 | 5499篇 |
耳鼻咽喉 | 45657篇 |
儿科学 | 100915篇 |
妇产科学 | 84931篇 |
基础医学 | 441407篇 |
口腔科学 | 89674篇 |
临床医学 | 283404篇 |
内科学 | 605806篇 |
皮肤病学 | 65589篇 |
神经病学 | 258122篇 |
特种医学 | 125330篇 |
外国民族医学 | 1301篇 |
外科学 | 474511篇 |
综合类 | 73936篇 |
一般理论 | 1235篇 |
预防医学 | 249842篇 |
眼科学 | 73411篇 |
药学 | 234868篇 |
6篇 | |
中国医学 | 5779篇 |
肿瘤学 | 164139篇 |
2018年 | 32001篇 |
2017年 | 24609篇 |
2016年 | 27068篇 |
2015年 | 30629篇 |
2014年 | 44104篇 |
2013年 | 67368篇 |
2012年 | 91616篇 |
2011年 | 96940篇 |
2010年 | 57190篇 |
2009年 | 54651篇 |
2008年 | 92085篇 |
2007年 | 98205篇 |
2006年 | 98851篇 |
2005年 | 96170篇 |
2004年 | 93064篇 |
2003年 | 90000篇 |
2002年 | 88446篇 |
2001年 | 145735篇 |
2000年 | 150749篇 |
1999年 | 127269篇 |
1998年 | 34926篇 |
1997年 | 31397篇 |
1996年 | 31275篇 |
1995年 | 32082篇 |
1994年 | 30097篇 |
1993年 | 28100篇 |
1992年 | 102917篇 |
1991年 | 100137篇 |
1990年 | 96718篇 |
1989年 | 93118篇 |
1988年 | 86215篇 |
1987年 | 84973篇 |
1986年 | 80192篇 |
1985年 | 76727篇 |
1984年 | 58126篇 |
1983年 | 49399篇 |
1982年 | 29693篇 |
1981年 | 26606篇 |
1979年 | 54113篇 |
1978年 | 37867篇 |
1977年 | 31973篇 |
1976年 | 30009篇 |
1975年 | 31954篇 |
1974年 | 39001篇 |
1973年 | 37180篇 |
1972年 | 34692篇 |
1971年 | 31926篇 |
1970年 | 30230篇 |
1969年 | 27966篇 |
1968年 | 25472篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献